Anaphylaxis Global Market Report 2025

The anaphylaxis market size has grown strongly in recent years. It will grow from $3.24 billion in 2024 to $3.51 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be attributed to several factors, including the rising prevalence of food allergies, which has led to more cases of anaphylaxis. Increased awareness of anaphylaxis and its potential risks has contributed to better understanding and faster responses to allergic reactions.

The anaphylaxis market size is expected to see strong growth in the next few years. It will grow to $4.81 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to several key factors, including increasing urbanization and lifestyle changes, which are contributing to a higher incidence of anaphylaxis cases. Rising disposable incomes in emerging markets are also enabling more people to access allergy treatments and medications. Government funding for allergy research is expected to spur innovation and improve treatment options. Additionally, advancements in delivery systems for emergency treatments, such as auto-injectors, are making it easier to manage anaphylaxis more effectively. Major trends in the forecast period include a growing demand for injectable auto-injectors, integration of digital health solutions to monitor and manage anaphylaxis, a focus on making treatments more affordable, the development of preventative treatments and vaccines, and the increased use of biologics in allergy treatment.

The increasing prevalence of food allergies is expected to drive the growth of the anaphylaxis market in the coming years. Food allergies are immune system reactions triggered by certain foods, causing symptoms that can range from mild to severe, including life-threatening anaphylaxis. The rising prevalence of food allergies can be attributed to factors such as changing dietary habits, environmental influences, and improved awareness and diagnosis. Anaphylaxis treatment plays a crucial role in providing life-saving intervention for food allergy patients, rapidly reversing severe allergic reactions, alleviating symptoms such as swelling, difficulty breathing, and a drop in blood pressure, ensuring immediate stabilization, and preventing potentially fatal outcomes. It also equips patients with tools for timely action in future allergic incidents. For example, in September 2024, the World Health Organization (WHO) reported that around 220 million people worldwide are affected by food allergies. A single food product can contain multiple allergens, and individuals may be allergic to more than one type of food. Additionally, the Food Standards Agency (FSA) released a report in May 2024 revealing that over 30% of adults in the UK experienced food-related adverse reactions, and clinical assessments confirmed food allergies in approximately 6% of UK adults, which equals around 2.4 million people. Thus, the increasing prevalence of food allergies is driving growth in the anaphylaxis market.

Companies in the anaphylaxis market are focused on advancing treatments, including the development of epinephrine nasal sprays that allow for faster and more efficient drug delivery in emergencies. Epinephrine nasal sprays are medical devices that administer epinephrine (adrenaline) through the nasal passages as a treatment for severe allergic reactions, including anaphylaxis. For example, in August 2024, ARS Pharmaceuticals, a US-based biotechnology company, announced that Neffy (epinephrine nasal spray) received approval from the US Food and Drug Administration (FDA), making it the first and only needle-free treatment for type I allergic reactions, including anaphylaxis. This innovative nasal spray provides a non-invasive alternative to traditional epinephrine autoinjectors, offering a potentially more accessible option for emergency treatment. Neffy aims to improve patient compliance by eliminating the need for needles while providing rapid, life-saving epinephrine during severe allergic reactions.

In October 2023, Nestlé Health Science SA, a Switzerland-based nutritional science company, partnered with Anaphylaxis UK to support individuals with severe allergies. This collaboration is designed to raise awareness about the serious consequences of anaphylaxis and empower individuals to manage allergies safely by providing education and resources. Anaphylaxis UK is a UK-based charity focused on severe allergies.

Major players in the anaphylaxis market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline Plc, F. Hoffman-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Perrigo Company plc, Dr Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals Inc., Mylan N.V., ALK-Abelló, Stallergenes Greer, Allergy Therapeutics.

North America was the largest region in the anaphylaxis market in 2024. The regions covered in anaphylaxis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anaphylaxis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anaphylaxis is a rapid, severe allergic reaction that can be life-threatening, leading to symptoms such as difficulty breathing, swelling, and a drop in blood pressure. It requires urgent medical attention, with epinephrine being the primary treatment to reverse the effects. After the administration of epinephrine, patients are monitored in a healthcare setting to stabilize their condition and avoid complications.

The main drug classes used in the management of anaphylaxis include epinephrine, steroids, antihistamines, beta-antagonists, and others. Epinephrine is crucial in reversing severe allergic reactions by constricting blood vessels, relaxing airway muscles, and increasing heart rate. These medications are administered through different routes such as parenteral, oral, and others, and are used to treat various types of allergic reactions, including those caused by food allergies, pollen, dust mites, and more.

The anaphylaxis market research report is one of a series of new reports that provides anaphylaxis market statistics, including anaphylaxis industry global market size, regional shares, competitors with an anaphylaxis market share, detailed anaphylaxis market segments, market trends and opportunities, and any further data you may need to thrive in the anaphylaxis industry. This anaphylaxis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anaphylaxis market consists of syringes and vials, intravenous (IV) epinephrine, diagnostic kits, and monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.